dc.contributor.author | Karadag O. | |
dc.contributor.author | Dalkilic E. | |
dc.contributor.author | Ayan G. | |
dc.contributor.author | Kucuksahin O. | |
dc.contributor.author | Kasifoglu T. | |
dc.contributor.author | Yilmaz N. | |
dc.contributor.author | Koca S.S. | |
dc.date.accessioned | 2024-02-04T13:30:04Z | |
dc.date.available | 2024-02-04T13:30:04Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 07703198 | |
dc.identifier.uri | https://doi.org/10.1007/s10067-021-05893-3 | |
dc.identifier.uri | http://hdl.handle.net/11446/4834 | |
dc.description.abstract | Objectives: To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment. Method: One hundred twenty patients with PsA receiving anti-TNF therapy were recruited to this noninterventional, observational study. Work disability was assessed via the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity was calculated via the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP) and Disease Activity Index for Psoriatic Arthritis with 28 joints (DAPSA28) score. Patient-reported outcomes (PROs), from visual analog scores and Health Assessment Questionnaire-Disability Index scores, were evaluated to understand the clinical effectiveness at baseline and every 3 months until the month-9 final visit. The American College of Rheumatology (ACR)20/50/70 response criteria were assessed at month 9. Results: A total of 120 patients (females, n = 73) were enrolled in the study. Mean (SD) age and disease duration were 41.6 ± 11.1 years and 6.9 ± 6.5 years, respectively. The most commonly used TNF? inhibitor was adalimumab (42.4%), followed by etanercept (25.8%). All WPAI questionnaire parameters were reduced at the follow-up visits compared with baseline (p < 0.001 for all). PROs and disease activity indicators (DAS28-CRP and DAPSA28) significantly improved during the course of anti-TNF treatments (p < 0.001 for all). Additionally, ACR20/50/70 responses were determined as 86.8%, 63.7%, and 41.8% of patients at the month-9 visit. Conclusions: The real-world data in PsA patients receiving anti-TNF treatment showed improvement in WPAI, QoL, and disease activity over 9 months of treatment. Trial registration: NCT02028169 • Psoriatic arthritis (PsA), with debilitating effects on quality of life, occurs mostly in young adults and has negative impacts on employment status and work productivity.• Early PsA diagnosis and treat-to-target treatment strategies aim to reduce pain and joint damage, as well as improve work productivity.• Real-world data on the impact of treatment with anti-tumor necrosis factor (anti-TNF) agents on work productivity in PsA in the literature is scarce.• Our study of real-world data in patients with PsA receiving anti-TNF treatment showed improvement in work productivity, as well as in clinical and patient-reported outcomes. © 2021, International League of Associations for Rheumatology (ILAR). | en_US |
dc.description.sponsorship | Roche; AbbVie; UCB | en_US |
dc.description.sponsorship | Omer Karadag: AbbVie (research grant, consulting fee), Pfizer (research grant, consulting fee), Roche (research grant, consulting fee), Novartis (research grant), Abdi İbrahim (consulting fee), Amgen (consulting fee), Farmanova (consulting fee), Janssen (consulting fee), Lilly (consulting fee), UCB (consulting fee). Ediz Dalkilic: AbbVie (speaker fee), MSD (speaker fee), Roche (speaker fee), Pfizer (speaker fee), UCB (speaker fee), Novartis (speaker fee). Gizem Ayan: None. Orhan Kucuksahin: None. Timucin Kasifoglu: AbbVie, Amgen, Roche, MSD, Novartis, Pfizer, and UCB (speaker and consulting fees). Neslihan Yilmaz: AbbVie (speaker fee), Pfizer (speaker fee), UCB (speaker fee), Roche (speaker fee), Janssen (speaker fee). Suleyman Serdar Koca: AbbVie (speaker fee), Pfizer (speaker fee), Roche (speaker fee), UCB (speaker fee), Novartis (speaker fee), Amgen (speaker fee), Pharmactive (speaker fee), MSD (speaker fee). Veli Yazisiz: AbbVie (consulting fee), Pfizer (consulting fee), UCB (consulting fee). Pinar Talu Erten: None. Mehmet Sayarlioglu: Genzyme (speaker fee), MSD (consulting fee), Novartis (research grant). Mehmet Ender Terzioglu: AbbVie, Pfizer, Novartis, Boehringer Ingelheim, Pharmactive, and UCB (speaker/consulting fee and/or research grant). Sukran Erten: Janssen (speaker fee), Roche (speaker fee), Novartis (speaker fee). Umut Kalyoncu: AbbVie, Pfizer (research grant, speaker, and consulting fee), Janssen (research grant, speaker fee), UCB, Novartis (speaker and consulting fee), Lilly (consulting fee). | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer Science and Business Media Deutschland GmbH | en_US |
dc.relation.ispartof | Clinical Rheumatology | en_US |
dc.identifier.doi | 10.1007/s10067-021-05893-3 | |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | ACR20/50/70 | en_US |
dc.subject | Anti-TNF | en_US |
dc.subject | DAPSA28 | en_US |
dc.subject | DAS28 | en_US |
dc.subject | Psoriatic arthritis | en_US |
dc.subject | Work disability | en_US |
dc.subject | adalimumab | en_US |
dc.subject | C reactive protein | en_US |
dc.subject | certolizumab pegol | en_US |
dc.subject | cyclosporine | en_US |
dc.subject | deflazacort | en_US |
dc.subject | diclofenac | en_US |
dc.subject | etanercept | en_US |
dc.subject | etodolac | en_US |
dc.subject | golimumab | en_US |
dc.subject | hydroxychloroquine | en_US |
dc.subject | infliximab | en_US |
dc.subject | leflunomide | en_US |
dc.subject | meloxicam | en_US |
dc.subject | methotrexate | en_US |
dc.subject | methylprednisolone | en_US |
dc.subject | naproxen | en_US |
dc.subject | prednisolone | en_US |
dc.subject | salazosulfapyridine | en_US |
dc.subject | tumor necrosis factor inhibitor | en_US |
dc.subject | adalimumab | en_US |
dc.subject | antirheumatic agent | en_US |
dc.subject | etanercept | en_US |
dc.subject | tumor necrosis factor | en_US |
dc.subject | tumor necrosis factor inhibitor | en_US |
dc.subject | achilles tendon | en_US |
dc.subject | adult | en_US |
dc.subject | age | en_US |
dc.subject | Article | en_US |
dc.subject | clinical effectiveness | en_US |
dc.subject | clinical outcome | en_US |
dc.subject | comparative study | en_US |
dc.subject | controlled clinical trial | en_US |
dc.subject | controlled study | en_US |
dc.subject | daily life activity | en_US |
dc.subject | DAS28 | en_US |
dc.subject | disease activity | en_US |
dc.subject | Disease Activity Index for Psoriatic Arthritis with 28 joints | en_US |
dc.subject | disease activity score | en_US |
dc.subject | disease duration | en_US |
dc.subject | erythrocyte sedimentation rate | en_US |
dc.subject | female | en_US |
dc.subject | follow up | en_US |
dc.subject | Health Assessment Questionnaire | en_US |
dc.subject | Health Assessment Questionnaire Disability Index | en_US |
dc.subject | household | en_US |
dc.subject | human | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | multicenter study | en_US |
dc.subject | observational study | en_US |
dc.subject | open study | en_US |
dc.subject | pain assessment | en_US |
dc.subject | patient-reported outcome | en_US |
dc.subject | physical activity | en_US |
dc.subject | postmarketing surveillance | en_US |
dc.subject | productivity | en_US |
dc.subject | prospective study | en_US |
dc.subject | psoriatic arthritis | en_US |
dc.subject | quality of life | en_US |
dc.subject | spinous process | en_US |
dc.subject | swollen joint count | en_US |
dc.subject | visual analog scale | en_US |
dc.subject | work disability | en_US |
dc.subject | psoriatic arthritis | en_US |
dc.subject | quality of life | en_US |
dc.subject | treatment outcome | en_US |
dc.subject | young adult | en_US |
dc.subject | Adalimumab | en_US |
dc.subject | Antirheumatic Agents | en_US |
dc.subject | Arthritis, Psoriatic | en_US |
dc.subject | Etanercept | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Quality of Life | en_US |
dc.subject | Treatment Outcome | en_US |
dc.subject | Tumor Necrosis Factor Inhibitors | en_US |
dc.subject | Tumor Necrosis Factor-alpha | en_US |
dc.subject | Young Adult | en_US |
dc.title | Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study | en_US |
dc.type | article | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.volume | 41 | en_US |
dc.identifier.startpage | 85 | en_US |
dc.identifier.endpage | 94 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | Karadag, O., School of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey; Dalkilic, E., School of Medicine, Department of Internal Medicine, Division of Rheumatology, Uludag University, Bursa, Turkey; Ayan, G., School of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey; Kucuksahin, O., Ankara City Hospital – School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara Yildirim Beyazit University, Ankara, Turkey; Kasifoglu, T., School of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University, Eskisehir, Turkey; Yilmaz, N., Istanbul Florence Nightingale Hospital, Department of Rheumatology, Demiroglu Bilim University, Istanbul, Turkey; Koca, S.S., School of Medicine, Department of Internal Medicine, Division of Rheumatology, Firat University, Elazig, Turkey; Yazisiz, V., School of Medicine, Department of Internal Medicine, Division of Rheumatology, Akdeniz University, Antalya, Turkey; Erten, P.T., Medical Park, Department of Internal Medicine, Division of Rheumatology, Izmir Economy University, Izmir, Turkey; Sayarlioglu, M., Department of Internal Medicine, Division of Rheumatology, Liv Hospital Samsun, Samsun, Turkey; Terzioglu, M.E., School of Medi | en_US |
dc.identifier.pmid | 34477993 | en_US |
dc.identifier.scopus | 2-s2.0-85114190305 | en_US |
dc.authorscopusid | 14630767100 | |
dc.authorscopusid | 6506739457 | |
dc.authorscopusid | 57192237533 | |
dc.authorscopusid | 14422446100 | |
dc.authorscopusid | 8392501600 | |
dc.authorscopusid | 35489690300 | |
dc.authorscopusid | 55667445900 | |